香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 有關就解決截至2024年12月31日止年度的 年度報告內無法表示意見所採取措施及行動的最新進展 創勝集團醫藥有限公司（「本公司」，連同其附屬公司統稱為「本集團」）董事會 （「董事會」）謹此向股東及潛在投資者提供有關就解決其截至2024年12月31日止年 度的年度報告（「年報」）內所載的無法表示意見（「無法表示意見」）所採取措施及 行動的執行進度的最新進展。本公告所用但並無另行界定的詞彙應與年報中所賦 予該等詞彙的涵義相同。 自於2025年4月22日刊發年報、於2025年7月11日刊發最新進展公告及於2025年 8月27日刊發中期業績公告以來，本集團就最初於年報內所載的九項關鍵措施持 續取得切實進展，該等措施旨在增強其財務狀況、提升流動性並解決無法表示意 見。有關執行 ...

Core Viewpoint - The company has completed the acquisition of a property in Irvine, California, for $4.365 million, and established a wholly-owned subsidiary, ETHK BANK, to enhance its operations in the North American market, focusing on stablecoin and intellectual property securitization [1][2]. Group 1: Property Acquisition - The acquired property, located at 9840 Irvine Center Drive, spans approximately 4,960 square feet and includes a two-story office building of about 9,920 square feet, designed for both office and research purposes [2]. - This property will serve as the company's strategic headquarters in the U.S., supporting the development of stablecoin public chain technology and intellectual property securitization, creating a hub for connecting global innovative assets with capital markets [2]. Group 2: ETHK BANK - ETHK BANK will act as the global operational platform for the company's stablecoin and intellectual property securitization business, managing core business directions including stablecoin licensing and compliance framework establishment [3]. - The company is pursuing a federal payment stablecoin issuer license under the U.S. GENIUS Act and plans to apply for a national trust bank license to create a compliant operational system [3]. - The company is developing an innovative stablecoin architecture that supports the generation of stablecoins pegged to the U.S. dollar through real-world asset collateral, aiming to provide a transparent and sustainable digital asset yield solution [3]. Group 3: Key Project Cooperation - The company has signed a strategic cooperation agreement with Transcenta Holding Limited for the tokenization of innovative drug pipeline assets valued at approximately $1.5 billion, with ETHK BANK leading the initiative [5]. - This project focuses on cutting-edge research in cancer treatment, providing a transparent and professional channel for global investors to access medical assets [5]. Group 4: Future Outlook - The acquisition of the U.S. property and the establishment of ETHK BANK signify the company's strategic upgrade towards becoming a global leader in stablecoin and high-tech intellectual property capital operations [6]. - The company aims to integrate on-chain financial infrastructure with the real economy, aligning with global digital economy trends and potentially opening new growth pathways [6]. - The board believes these initiatives reflect the company's core philosophy of transforming knowledge into capital, ensuring long-term stable returns for shareholders through compliant capital operations and innovative practices [6].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公 司） （股份代號：1931） 收購美國物業及設立美國附屬公司ETHK BANK 於美國推進穩定幣及知識產權證券化新征程 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 的 最 新 資 料。 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，本 公 司 已 於 近 期 完 成 收 購 位 於 美 國 加 利 福 尼 亞 州 奧 蘭 治 縣 爾 灣 市 一 處 物 業（「該物業」），總 代 價 為436.5萬 美 元。同 時， 本公司於美國科羅拉多州註冊成立全資附屬公 ...

Core Viewpoint - Several biotechnology companies, including Sanofi Biologics, Innovent Biologics, and Rongchang Biologics, experienced significant stock declines, with drops exceeding 10% [1] Company Performance - Sanofi Biologics, Innovent Biologics, and Rongchang Biologics all saw their stock prices fall by more than 10% [1] - Other companies such as Gilead Sciences, Chuangsheng Group, and Jakeson also faced declines, with drops exceeding 9% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 公司名稱: 創勝集團醫藥有限公司（以存續方式於開曼群島註冊的有限公司） 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06628 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 | USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 | USD | | 1,000,000 | 本 ...

Group 1 - The chairman of the board, Qian Xueming, increased his stake in Chuangsheng Group (06628) by purchasing 10,000 shares at a price of HKD 4.6225 per share, totaling approximately HKD 46,225 [1] - After the purchase, the latest number of shares held by Qian Xueming is 37.956 million, representing a holding percentage of 8.39% [1]

Core Viewpoint - The chairman of the board, Qian Xueming, has increased his stake in Chuangsheng Group (06628) by purchasing 10,000 shares at a price of HKD 4.6225 per share, totaling approximately HKD 46,225, which raises his total holdings to 37.956 million shares, representing 8.39% of the company [1] Summary by Category - **Share Purchase Details** - Qian Xueming acquired 10,000 shares at HKD 4.6225 each [1] - The total investment amounts to approximately HKD 46,225 [1] - **Current Holdings** - After the purchase, Qian Xueming's total shareholding is 37.956 million shares [1] - This represents an ownership stake of 8.39% in Chuangsheng Group [1]

Group 1 - The chairman of the board, Qian Xueming, increased his stake in Chuangsheng Group (06628) by purchasing 20,000 shares at a price of HKD 4.16 per share, totaling approximately HKD 83,200 [1] - Following the purchase, the latest number of shares held by Qian Xueming is 37.946 million, representing an ownership percentage of 8.39% [1]

Core Viewpoint - The chairman of the board, Qian Xueming, increased his stake in Chuangsheng Group (06628) by purchasing 20,000 shares at a price of HKD 4.16 per share, totaling approximately HKD 83,200, which reflects a commitment to the company's future growth [1] Summary by Category Shareholding Activity - Qian Xueming's latest shareholding after the purchase is 37.946 million shares, representing an ownership stake of 8.39% in Chuangsheng Group [1]

Core Viewpoint - Chuangsheng Group-B (06628) has seen a significant stock price increase of over 10%, currently trading at 4.82 HKD, following the announcement of a strategic cooperation agreement with Huajian Medical (01931) regarding the potential tokenization of innovative drug pipeline assets [1] Group 1: Strategic Cooperation - Chuangsheng Group has entered into a strategic cooperation agreement with Huajian Medical to explore the tokenization of its innovative drug pipeline assets [1] - The agreement involves integrating six core innovative drug pipeline assets (TST003, TST005, TST786, TST105, TST106, and TST013) into its U.S. entity [1] - The collaboration aims to utilize Huajian Medical's ETHK global innovative drug intellectual property RWA exchange for potential RWA tokenization [1] Group 2: Funding and Development - If the token issuance is successful, the proceeds will be used to accelerate the clinical and preclinical development of several innovative antibody projects targeting tumors [1] - The Chairman of Chuangsheng Group, Dr. Qian Xueming, emphasized the need for substantial funding in the long and high-risk process of drug development [1] - The partnership with Huajian Medical's on-chain RWA digital platform will provide a new funding channel by allowing the intellectual property of innovative drug pipelines to be packaged into a U.S. SPV for novel financing [1]